NICE rejects Pfizer’s rare heart disease treatment Vyndaqel
The final guidance publication comes following an appeal against earlier draft recommendations
Read More
Tag: transthyretin amyloidosis with cardiomyopathy
- Lario Therapeutics awarded $2.4m to advance calcium channel platform
- Mikrobiomik secures approval for gut‑microbiota therapy for C difficile infection
- Exdensur approved in EU for severe asthma and CRSwNP
- Axol Bioscience acquires Newcells Biotech ophthalmology unit
- Nuclera and leadXpro partner to accelerate structure‑based drug design
